Featured Video
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Our Experts
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
- CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
- CIDP
- GBS
- MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
- MMN
Dr. Hans Katzberg is a neuromuscular specialist and clinical investigator at the University Health Network / Toronto General Hospital and has been on faculty at the University of Toronto as Assistant Professor of Neurology.
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
- CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Back to Top